TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9492131

Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac (60 mg)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Oral ibuprofen (800 mg)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Both treatments (ketorolac and ibuprofen)
Number of subjects: 119
Study: 11271189

Group type: EXPERIMENTAL
Intervention: FK 506
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclosporin
Number of subjects: 0
Study: 2577273

Group type: COMPARATOR
Intervention: Maintenance drug treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug withdrawal
Number of subjects: 0
Study: 792740

Group type: EXPERIMENTAL
Intervention: Parsalmide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Phenylbutazone
Number of subjects: 30
Study: 31802596

Group type: EXPERIMENTAL
Intervention: Non-invasive vagal nerve stimulation (nVNS) using gammaCore for 4 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Non-invasive vagal nerve stimulation (nVNS)
Number of subjects: 15
Study: 31707181

Group type: EXPERIMENTAL
Intervention: Modified gemcitabine and oxaliplatin (mGemOx) - gemcitabine 900 mg/m2, oxaliplatin 80 mg/m2, maximum 6 cycles
Number of subjects: 243

Group type: COMPARATOR
Intervention: Gemcitabine + cisplatin (CisGem) - gemcitabine 1000 mg/m2, cisplatin 25 mg/m2, maximum 8 cycles
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Overall group
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Modified gemcitabine and oxaliplatin (mGemOx)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Gemcitabine + cisplatin (CisGem)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Overall comparison
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Toxicities
Number of subjects: 243
Study: 28893900

Group type: EXPERIMENTAL
Intervention: Labetalol (200‐1800 mg/d)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Nifedipine (20‐80 mg/d)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 112
Study: 26049688

Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (EBRT)
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Substantial LVSI (3-tiered approach)
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Any degree of LVSI
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Substantial LVSI
Number of subjects: 926
Study: 23764884

Group type: EXPERIMENTAL
Intervention: KinesioTaping
Number of subjects: 25

Group type: COMPARATOR
Intervention: ShamTaping
Number of subjects: 25
Study: 21946743

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 19689824

Group type: EXPERIMENTAL
Intervention: Kneipp hydrotherapy (daily, with alternate cold and warm thigh affusions)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy (three times a week)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Combination of physiotherapy and hydrotherapy (joint-specific physiotherapy three times a week and daily alternate cold and warm thigh affusions)
Number of subjects: 180
Study: 16965728

Group type: EXPERIMENTAL
Intervention: Strict blood pressure control
Number of subjects: 1093

Group type: EXPERIMENTAL
Intervention: ACEI-based therapy
Number of subjects: 1093

Group type: EXPERIMENTAL
Intervention: CCB-based regimen with strict BP control
Number of subjects: 1093

Group type: EXPERIMENTAL
Intervention: Proteinuria
Number of subjects: 1093
Study: 16876495

Group type: EXPERIMENTAL
Intervention: LOWER (lower body resistance plus jump exercise)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: UPPER + LOWER (lower and upper body resistance plus jump exercise)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: UPPER + LOWER
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: LOWER
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 59
Study: 12607495

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha interferon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation
Number of subjects: 0
Study: 10602973

Group type: EXPERIMENTAL
Intervention: iopromide 240 mgI/ml
Number of subjects: 421

Group type: COMPARATOR
Intervention: iohexol 240 mgI/ml
Number of subjects: 421
Study: 8529760

Group type: EXPERIMENTAL
Intervention: Insulin (0.3 IU/Kg BW at 10-11 p.m.)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Acarbose (3 x 100 mg daily)
Number of subjects: 36
Study: 1952145

Group type: EXPERIMENTAL
Intervention: ocfentanil 1 microgram/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ocfentanil 3 micrograms/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ocfentanil 5 micrograms/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: fentanyl 5 micrograms/kg
Number of subjects: 60
Study: 7113951

Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted diet (827 kcal; 35% protein, 64% fat, 1% carbohydrate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbohydrate-containing diet (827 kcal; 35% protein, 36% fat, 29% carbohydrate)
Number of subjects: 0
Study: 31791824

Group type: EXPERIMENTAL
Intervention: 40 U DaxibotulinumtoxinA (DAXI)
Number of subjects: 609

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 609
Study: 29623579

Group type: EXPERIMENTAL
Intervention: Oral semaglutide (5 mg for 5 days followed by 10 mg for 5 days)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 91
Study: 27574886

Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration (HVHF)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin combined with insulin (LMWH+insulin)
Number of subjects: 66
Study: 26718754

Group type: COMPARATOR
Intervention: Endoscopic urethrotomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open urethroplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study: 23564725

Group type: EXPERIMENTAL
Intervention: Web-based training program
Number of subjects: 27
Study: 19406493

Group type: EXPERIMENTAL
Intervention: Enoxaparin and unfractionated heparin (no specific dosage or duration mentioned)
Number of subjects: 9838
Study: 18339730

Group type: EXPERIMENTAL
Intervention: CIM
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: CIP/CIM
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: CIP
Number of subjects: 92
Study: 16641396

Group type: EXPERIMENTAL
Intervention: Vitamin C (1000 mg) and Vitamin E (400 IU) supplementation
Number of subjects: 1877

Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Number of subjects: 1877
Study: 12932879

Group type: EXPERIMENTAL
Intervention: Vaginal myomectomy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Laparoscopic myomectomy
Number of subjects: 24
Study: 10993394

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9068393

Group type: EXPERIMENTAL
Intervention: 100 mg alteplase
Number of subjects: 25
Study: 1350141

Group type: EXPERIMENTAL
Intervention: TEWL measurements next to the wrist
Number of subjects: 14

Group type: COMPARATOR
Intervention: Other volar forearm sites
Number of subjects: 14
Study: 4009330

Group type: EXPERIMENTAL
Intervention: Oral rehydration with solution A and solution B
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous therapy
Number of subjects: 100
Study: 29280064

Group type: EXPERIMENTAL
Intervention: Macitentan in combination with background therapy (PDE‐5i)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Background therapy only (placebo arm)
Number of subjects: 0
Study: 26194532

Group type: EXPERIMENTAL
Intervention: GnRH antagonist analogue administered at a dose interval of 3 days and/or a monthly dose of GnRHa during chemotherapy
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: GnRH antagonist analogue
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: GnRH analogues
Number of subjects: 38
Study: 25450320

Group type: EXPERIMENTAL
Intervention: Protoconized anemia therapy with adjusted doses of erythropoietin, iron, and vitamin C based on Hb and ferritin levels.
Number of subjects: 266

Group type: COMPARATOR
Intervention: Non‐intervention group with doses of erythropoietin and iron determined by the attending physician.
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Higher maintenance rate of target Hb levels.
Number of subjects: 266

Group type: COMPARATOR
Intervention: Lower maintenance rate of target Hb levels.
Number of subjects: 266
Study: 22435409

Group type: EXPERIMENTAL
Intervention: Essential oil group (n = 24) using blended essential oils (lavender, clary sage, marjoram) in a 3% concentration cream, massaged daily on lower abdomen.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Synthetic fragrance group (n = 24) as control.
Number of subjects: 48
Study: 20077275

Group type: EXPERIMENTAL
Intervention: Overtrained athletes
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control athletes
Number of subjects: 12
Study: 18344428

Group type: EXPERIMENTAL
Intervention: Pilocarpine, 5 mg orally every 8 hours for 1 week after 131I therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (standard care with dexamethasone and dolasetron mesylate)
Number of subjects: 60
Study: 16471104

Group type: EXPERIMENTAL
Intervention: 25G Quincke spinal needle
Number of subjects: 10

Group type: COMPARATOR
Intervention: 27G Quincke spinal needle
Number of subjects: 10
Study: 14560224

Group type: EXPERIMENTAL
Intervention: Immediate open surgical AAA repair
Number of subjects: 1136

Group type: COMPARATOR
Intervention: Imaging surveillance every 6 months
Number of subjects: 1136
Study: 10556111

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microgram twice daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fluticasone (100 microgram twice daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 8739023

Group type: EXPERIMENTAL
Intervention: 0.1 mg Y-27152
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 0.25 mg Y-27152
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 0.5 mg Y-27152
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 0.75 mg Y-27152 (fasting)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 0.75 mg Y-27152 (after food)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 1.0 mg Y-27152
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 0.5 mg Y-27152 (multiple doses)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 0.75 mg Y-27152 (multiple doses)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 1.0 mg Y-27152 (multiple doses)
Number of subjects: 27
Study: 2020506

Group type: EXPERIMENTAL
Intervention: Standard advice plus recommendation to increase supplemental carrying by 50% (supplemental group)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard pediatric advice (standard group)
Number of subjects: 66
Study: 6750476

Group type: EXPERIMENTAL
Intervention: Sodium cephalothin
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 31477166

Group type: EXPERIMENTAL
Intervention: NRT2Quit app (full version)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control app (minimal version)
Number of subjects: 41
Study: 29631362

Group type: EXPERIMENTAL
Intervention: GnRHAG + E2
Number of subjects: 30

Group type: COMPARATOR
Intervention: GnRHAG + PL
Number of subjects: 30
Study: 26746580

Group type: EXPERIMENTAL
Intervention: Gratitude writing intervention (writing letters expressing gratitude)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Therapy-as-usual control group (no writing intervention)
Number of subjects: 0
Study: 24852722

Group type: EXPERIMENTAL
Intervention: BCG vaccination at school age (first dose)
Number of subjects: 239934

Group type: EXPERIMENTAL
Intervention: BCG revaccination at school age
Number of subjects: 239934

Group type: EXPERIMENTAL
Intervention: Neonatal BCG vaccination
Number of subjects: 239934
Study: 22865627

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (30% heart rate reserve) for 25-40 min/session
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Vigorous-intensity exercise (70% heart rate reserve) for 25-40 min/session
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (30% heart rate reserve) for 35-40 min/session
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (30% heart rate reserve) for 25 min/session
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Vigorous-intensity exercise (70% heart rate reserve) for 25 min/session
Number of subjects: 56
Study: 20609482

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI, escitalopram)
Number of subjects: 728

Group type: COMPARATOR
Intervention: Tricyclic antidepressant (TCA, nortriptyline)
Number of subjects: 728
Study: 17921366

Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal (300 kcal, 100% carbohydrate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-fat meal (30 g fat/m(2), 35% fat)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard test meal (478 kcal; 16.4% protein, 32.7% fat, 50.4% carbohydrate)
Number of subjects: 0
Study: 16120118

Group type: EXPERIMENTAL
Intervention: Fluconazole capsules (Zolax 50 mg once a day)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Hexetidine mouthrinses (Heksoral 0.1%, twice daily)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Fluconazole capsules and hexetidine mouthrinses for 14 days
Number of subjects: 61
Study: 11934186

Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal treatment (debridement and short-term usage of antimicrobial agents)
Number of subjects: 90
Study: 10386179

Group type: EXPERIMENTAL
Intervention: AMPT
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8695556

Group type: EXPERIMENTAL
Intervention: Peribulbar injections of 5 ml of anaesthetic (study group 1)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Peribulbar injections of local anaesthetic (study group 2)
Number of subjects: 56
Study: 2062516

Group type: EXPERIMENTAL
Intervention: Early photocoagulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deferral of photocoagulation (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluorescein leakage severity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capillary loss and dilatation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arteriolar abnormalities
Number of subjects: 0
Study: 6132832

Group type: EXPERIMENTAL
Intervention: Theophylline (300 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 31145202

Group type: COMPARATOR
Intervention: Conjugated equine estrogens (CEE) alone (0.625 mg/d)
Number of subjects: 27347

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) with calcium and vitamin D supplementation (CaD)
Number of subjects: 27347

Group type: COMPARATOR
Intervention: CEE + medroxyprogesterone acetate (MPA) (0.625 mg of CEE + 2.5 mg of MPA)
Number of subjects: 27347
Study: 29203070

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting bioresorbable polymer stent (MiStent)
Number of subjects: 1398

Group type: COMPARATOR
Intervention: Everolimus-eluting durable polymer stent (Xience)
Number of subjects: 1398
Study: 27030534

Group type: EXPERIMENTAL
Intervention: Low-AGE diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-AGE diet
Number of subjects: 20
Study: 24655054

Group type: EXPERIMENTAL
Intervention: SGA preterm infants
Number of subjects: 131

Group type: COMPARATOR
Intervention: AGA preterm infants
Number of subjects: 131
Study: 22835668

Group type: EXPERIMENTAL
Intervention: Second-generation everolimus-eluting stents (EES)
Number of subjects: 625

Group type: COMPARATOR
Intervention: First-generation sirolimus-eluting stents (SES)
Number of subjects: 625
Study: 20642246

Group type: EXPERIMENTAL
Intervention: Tapentadol IR 50 or 100 mg
Number of subjects: 849

Group type: COMPARATOR
Intervention: Oxycodone HCI IR 10 or 15 mg
Number of subjects: 849
Study: 17643772

Group type: EXPERIMENTAL
Intervention: 3 intradermal doses of 0.1 mL PCECV (Rabipur)
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: 2 simulated post‐exposure booster doses 1 year after primary vaccination
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: PCECV (Rabipur)
Number of subjects: 703
Study: 16224180

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy with biweekly administration of 1,000 mg/m² gemcitabine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 19
Study: 15457754

Group type: EXPERIMENTAL
Intervention: Scoliosis in-patient rehabilitation (SIR) program offering patient-specific physiotherapy including intensive therapist-assisted exercise for six weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated patients (control group).
Number of subjects: 0
Study: 11157177

Group type: EXPERIMENTAL
Intervention: Manual tracing of the perimeter
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Single largest diameter
Number of subjects: 38
Study: 9526937

Group type: EXPERIMENTAL
Intervention: High concentration sevoflurane (8% in 2:1 N2O:O2 mixture)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Incremental sevoflurane (1% in 2:1 N2O:O2 mixture, increased by 1% every 2-3 breaths)
Number of subjects: 40
Study: 7983291

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 422

Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 422
Study: 2643772

Group type: EXPERIMENTAL
Intervention: High-dose subcutaneous heparin (12,500 units every 12 hours)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Low-dose subcutaneous heparin (5000 units every 12 hours)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: High-dose subcutaneous heparin
Number of subjects: 221

Group type: COMPARATOR
Intervention: Low-dose subcutaneous heparin
Number of subjects: 221
Study: 969073

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cyclophosphamide (Cytoxan)
Number of subjects: 0

Group type: COMPARATOR
Intervention: standard therapy
Number of subjects: 0
Study: 7409300

Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg o.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibuprofen (200 mg t.i.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29962180

Group type: EXPERIMENTAL
Intervention: Rosuvastatin in combination with nimodipine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nimodipine (control group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Adverse reactions
Number of subjects: 120
Study: 29687966

Group type: EXPERIMENTAL
Intervention: Spinal manipulation plus laser therapy and exercise (SM-LT-CE)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Laser therapy and exercise (LT-CE)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 330
Study: 27412459

Group type: EXPERIMENTAL
Intervention: Social action volunteer befriending service plus usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list arm (control)
Number of subjects: 0
Study: 24860893

Group type: EXPERIMENTAL
Intervention: Pertuzumab + trastuzumab + docetaxel
Number of subjects: 808
Study: 22824834

Group type: EXPERIMENTAL
Intervention: 12 mcg/h fentanyl patch
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo control patch
Number of subjects: 110
Study: 21287795

Group type: EXPERIMENTAL
Intervention: Computerized continuous performance functions test (CPF test)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (non-ADHD children)
Number of subjects: 58
Study: 17517060

Group type: EXPERIMENTAL
Intervention: Methodological and statistical features of RCTs in implant therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived clinical relevance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Impact on research
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methodological and statistical quality of studies
Number of subjects: 0
Study: 16163087

Group type: EXPERIMENTAL
Intervention: Silicone gel
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 50
Study: 11904104

Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 288

Group type: COMPARATOR
Intervention: Praziquantel
Number of subjects: 288
Study: 10527977

Group type: EXPERIMENTAL
Intervention: Norplant implants (NOR)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Progesterone vaginal rings (PVR)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Copper T 380A intrauterine devices (T-Cu)
Number of subjects: 108
Study: 7588177

Group type: EXPERIMENTAL
Intervention: Antidepressants (full dosage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long term antidepressants (in bipolar disorders)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long term antidepressants (in dysthymias and personality disorders)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tricyclics, MAOIs, and SSRIs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long term antidepressant treatment
Number of subjects: 0
Study: 2012292

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia with higher infusion rate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Patient-controlled epidural analgesia with lower infusion rate
Number of subjects: 50
Study: 7044724

Group type: EXPERIMENTAL
Intervention: Oral preoperative antibiotics and systemic peroperative antibiotics
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oral preoperative antibiotics
Number of subjects: 90

Group type: COMPARATOR
Intervention: Systemic peroperative antibiotics
Number of subjects: 90
Study: 31043346

Group type: EXPERIMENTAL
Intervention: PAAS technology
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: In-person facilitator-led PAAS small group
Number of subjects: 412

Group type: COMPARATOR
Intervention: Literature control (home-mailed educational materials)
Number of subjects: 412
Study: 29961920

Group type: EXPERIMENTAL
Intervention: Recombinant human EPO (rhEPO) administered acutely to healthy humans.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant human EPO (rhEPO) administered acutely to mice.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic elevation of EPO in transgenic mice.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute injections of recombinant FGF23.
Number of subjects: 0